Valion Bio (VBIO) Cash from Operations (2021 - 2025)

Valion Bio has reported Cash from Operations for 5 years, with the latest figure at -$2.3 million in Q4 2025.

• On a quarterly basis, Cash from Operations fell 72.68% year-over-year to -$2.3 million in Q4 2025; TTM through Dec 2025 was -$7.0 million, a 22.27% decrease from a year earlier, with the FY2025 full-year figure at -$7.0 million, down 22.27% from the prior year.
• Cash from Operations was -$2.3 million for Q4 2025 at Valion Bio, down from -$2.0 million in the prior quarter.
• The five-year high for Cash from Operations was -$543000.0 in Q2 2021, with the low at -$2.8 million in Q3 2022.
• Average Cash from Operations over 5 years is -$1.8 million, with a median of -$1.8 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: Cash from Operations plunged 230.83% in 2022, then surged 47.45% in 2024.
• Over 5 years, Cash from Operations stood at -$2.8 million in 2021, then advanced by 19.6% to -$2.2 million in 2022, then climbed by 20.05% to -$1.8 million in 2023, then advanced by 25.31% to -$1.3 million in 2024, then sank by 72.68% to -$2.3 million in 2025.
• The last three Cash from Operations figures came in at -$2.3 million (Q4 2025), -$2.0 million (Q3 2025), and -$1.8 million (Q2 2025), per Business Quant data.